Stoke Therapeutics (STOK) Stock Price
Stoke Therapeutics Price
Over the last 4 years Stoke Therapeutics grew revenue by 180.0% annually, reaching 184.42 M USD. For Stoke Therapeutics, the net margin of -3.7% is up versus -2,823.7% a few years ago. The consensus 12-month price target for Stoke Therapeutics is 44.00 USD, about 81.1% above where the stock trades today. Of 20 analysts, 19 rate the stock a buy — an overall Buy consensus.
Stoke Therapeutics stock price
Stoke Therapeutics business model & stock analysis
Frequently asked questions about Stoke Therapeutics
The business model of Stoke Therapeutics Inc revolves around developing innovative RNA-targeted therapeutics to treat severe genetic diseases. By focusing on addressing the underlying causes of diseases, Stoke Therapeutics aims to provide long-term solutions for patients. Its proprietary technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO), enables the modulation of gene expression levels to restore the production of functional proteins. Stoke Therapeutics collaborates with industry partners and utilizes its expertise in RNA biology to advance potential therapies for a range of genetic disorders. Through its business model, the company aims to improve the lives of patients with severe genetic diseases through innovative and targeted treatments.
Stoke Therapeutics Inc is primarily active in the biotechnology industry.
The main competitors of Stoke Therapeutics Inc in the market include companies such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Akcea Therapeutics.
Stoke Therapeutics Inc is a biotechnology company founded in 2018, based in Bedford, Massachusetts. Focused on addressing the underlying causes of severe genetic diseases, Stoke Therapeutics utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform enables the development of antisense oligonucleotide (ASO) therapies to increase protein levels and restore gene expression. By targeting RNA instead of DNA, Stoke Therapeutics aims to treat a range of genetic disorders, including genetic epilepsies, genetic conditions affecting the central nervous system, and other rare diseases. Their innovative approach holds promise for patients with limited treatment options, making Stoke Therapeutics a key player in the biotech industry.
Stoke Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering in June 2019, raising approximately $142 million in net proceeds. In January 2020, Stoke Therapeutics received the FDA's rare pediatric disease designation for its lead product candidate, STK-001, which aims to treat Dravet syndrome, a severe form of epilepsy. Furthermore, the company initiated a Phase 1/2a clinical trial of STK-001 in October 2020. Stoke Therapeutics continues to make progress in advancing its pipeline and developing innovative therapies for genetic diseases.
Stoke Therapeutics Inc is primarily present in the United States.
Stoke Therapeutics Inc represents values of innovation, collaboration, and commitment to patients. The company's corporate philosophy revolves around developing transformative treatments for severe genetic diseases. Stoke is dedicated to harnessing the power of RNA biology to address the underlying cause of such diseases. By prioritizing scientific advancement and partnerships, Stoke Therapeutics Inc aims to make a positive impact on patients' lives. The company strives to excel in translating cutting-edge research into therapeutic breakthroughs, offering hope and delivering long-term value for patients, their families, and the healthcare community.
Analysts currently set an average price target of 47.33 USD for the Stoke Therapeutics stock (median: 44.00 USD), implying +94.9 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Stoke Therapeutics stock: 19 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Stoke Therapeutics to generate revenue of 32.03 M USD and earnings per share of -3.54 USD.
Converted at the current exchange rate, the Stoke Therapeutics share trades at 21.69 EUR (24.29 USD).
The Stoke Therapeutics share (STOK) is listed on 3 stock exchanges, including: NASDAQ (STOK), Frankfurt (0GT.F), München (0GT.MU).
Stoke Therapeutics Inc. is a biopharmaceutical company focused on developing technologies and therapies for the treatment of rare genetic diseases. Their business model is based on the application of a novel technology platform called Targeted Augmentation of Nuclear Gene Output (TANGO), which allows for the increase or decrease of gene expression. They aim to achieve therapeutic effects by specifically augmenting gene expression through their TANGO platform, which involves developing RNA molecules known as antisense oligonucleotides (ASOs) to modulate gene expression. Stoke Therapeutics has multiple products in various stages of development, with their most advanced candidate, STK-001, targeting the treatment of autosomal recessive spinobulbar muscular atrophy (SMA). They are also working on therapies for other rare diseases such as autosomal dominant optic atrophy (ADOA) and Dravet syndrome. Overall, Stoke Therapeutics focuses on developing RNA-based therapeutics for rare genetic diseases caused by loss-of-function mutations.
The expected revenue of Stoke Therapeutics is 32.03 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Stoke Therapeutics is -206.73 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Stoke Therapeutics is currently -6.86. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Stoke Therapeutics stock.
The price-to-sales ratio (P/S) of Stoke Therapeutics is currently 44.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Stoke Therapeutics stock.
The Eulerpool Quality Score for Stoke Therapeutics is 3/10.
The ISIN of Stoke Therapeutics is US86150R1077. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Stoke Therapeutics is A2PLTL. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Stoke Therapeutics is STOK. The ticker symbol is used to trade Stoke Therapeutics shares on the stock exchange.
Stoke Therapeutics stock
Stoke Therapeutics Peer Group
Stoke Therapeutics Ticker
Stoke Therapeutics FIGI
All fundamentals and in-depth analysis of Stoke Therapeutics
Our stock analysis for Stoke Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stoke Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.